Sex differences in hypertension among people living with HIV after initiation of antiretroviral therapy.
HIV
blood pressure
dolutegravir
incident hypertension
lopinavir
protease inhibitors
sex differences
Journal
Frontiers in cardiovascular medicine
ISSN: 2297-055X
Titre abrégé: Front Cardiovasc Med
Pays: Switzerland
ID NLM: 101653388
Informations de publication
Date de publication:
2022
2022
Historique:
received:
29
07
2022
accepted:
31
10
2022
entrez:
5
12
2022
pubmed:
6
12
2022
medline:
6
12
2022
Statut:
epublish
Résumé
Hypertension is common in people living with HIV (PLWH) on antiretroviral therapy (ART). In the general population and in experimental animal models, the incidence of hypertension is greater in males than in females, especially during the premenopausal period. However, it is not known whether there are sex differences in hypertension associated with HIV and ART, and the factors contributing to incident hypertension among PLWH have not been well characterized. In this study, we aimed to determine the time course, sex differences and factors associated with incident hypertension in PLWH initiating ART. We conducted a retrospective study in which we used programmatic data from the ART registry to identify sex differences in the determinants of incident hypertension among PLWH initiating the ART regimen from Livingstone University Teaching Hospital in Zambia and followed for 8 years. Males developed hypertension earlier, 2 years after initiating ART, compared to 6 years in females. In multivariable analysis, increasing age, baseline systolic blood pressure and baseline mean arterial pressure (MAP) were associated with increased risk for developing incident hypertension. Also, participants who switched to the integrase strand transfer inhibitor, dolutegravir (DTG) or the protease inhibitor, lopinavir boosted with ritonavir were 2 and 3 times more likely to develop hypertension when compared to those on non-nucleoside reverse transcriptase inhibitors (NNRTIs). However, these relationships were abrogated by sex, as self-reported male sex was the major contributor in predicting incident hypertension. While none of the factors remained significantly associated with incident hypertension upon multivariate analysis among females, body mass index (BMI), and use of protease inhibitors remained strongly associated with hypertension among males. Our results indicate that the use of protease inhibitors and BMI are important predictors of incident hypertension among males. Thus, blood pressure and BMI should be closely monitored, particularly in males living with HIV on protease inhibitors. In addition, identifying specific factors that protect females from developing hypertension early is important but remains to be determined.
Sections du résumé
Background
UNASSIGNED
Hypertension is common in people living with HIV (PLWH) on antiretroviral therapy (ART). In the general population and in experimental animal models, the incidence of hypertension is greater in males than in females, especially during the premenopausal period. However, it is not known whether there are sex differences in hypertension associated with HIV and ART, and the factors contributing to incident hypertension among PLWH have not been well characterized. In this study, we aimed to determine the time course, sex differences and factors associated with incident hypertension in PLWH initiating ART.
Methods and results
UNASSIGNED
We conducted a retrospective study in which we used programmatic data from the ART registry to identify sex differences in the determinants of incident hypertension among PLWH initiating the ART regimen from Livingstone University Teaching Hospital in Zambia and followed for 8 years. Males developed hypertension earlier, 2 years after initiating ART, compared to 6 years in females. In multivariable analysis, increasing age, baseline systolic blood pressure and baseline mean arterial pressure (MAP) were associated with increased risk for developing incident hypertension. Also, participants who switched to the integrase strand transfer inhibitor, dolutegravir (DTG) or the protease inhibitor, lopinavir boosted with ritonavir were 2 and 3 times more likely to develop hypertension when compared to those on non-nucleoside reverse transcriptase inhibitors (NNRTIs). However, these relationships were abrogated by sex, as self-reported male sex was the major contributor in predicting incident hypertension. While none of the factors remained significantly associated with incident hypertension upon multivariate analysis among females, body mass index (BMI), and use of protease inhibitors remained strongly associated with hypertension among males.
Conclusion
UNASSIGNED
Our results indicate that the use of protease inhibitors and BMI are important predictors of incident hypertension among males. Thus, blood pressure and BMI should be closely monitored, particularly in males living with HIV on protease inhibitors. In addition, identifying specific factors that protect females from developing hypertension early is important but remains to be determined.
Identifiants
pubmed: 36465432
doi: 10.3389/fcvm.2022.1006789
pmc: PMC9715396
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1006789Subventions
Organisme : FIC NIH HHS
ID : D43 TW009744
Pays : United States
Informations de copyright
Copyright © 2022 Masenga, Povia, Mutengo, Hamooya, Nzala, Heimburger, Munsaka, Elijovich, Patel and Kirabo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Hypertens. 2007 Oct;20(10):1045-50
pubmed: 17903686
Kidney Int. 2018 Mar;93(3):545-559
pubmed: 29398134
Hypertension. 2001 May;37(5):1199-208
pubmed: 11358929
J Am Heart Assoc. 2020 Feb 18;9(4):e011450
pubmed: 32064996
Hypertension. 2018 Jul;72(1):44-55
pubmed: 29776989
BMC Public Health. 2020 Jun 1;20(1):834
pubmed: 32487185
Eur J Nutr. 2012 Oct;51(7):861-70
pubmed: 22042005
Clin Infect Dis. 2016 Jul 15;63(2):242-8
pubmed: 27090989
Hypertens Res. 2017 Dec;40(12):947-963
pubmed: 28978986
J Clin Hypertens (Greenwich). 2021 Jun;23(6):1129-1132
pubmed: 33605013
J Clin Hypertens (Greenwich). 2020 Sep;22(9):1554-1562
pubmed: 32815636
AIDS. 2006 Apr 24;20(7):1019-26
pubmed: 16603854
BMC Infect Dis. 2017 Aug 9;17(1):551
pubmed: 28793863
J Acquir Immune Defic Syndr. 2016 Dec 1;73(4):396-402
pubmed: 27171743
PLoS One. 2017 Mar 8;12(3):e0172089
pubmed: 28273105
Integr Blood Press Control. 2019 Sep 10;12:23-31
pubmed: 31564965
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Curr Hypertens Rep. 2019 Jun 4;21(7):56
pubmed: 31165257
Am J Hypertens. 2018 Nov 13;31(12):1247-1254
pubmed: 30299518
Am J Hypertens. 2020 Jan 1;33(1):43-52
pubmed: 31800000
Int J Hypertens. 2021 Aug 26;2021:5515832
pubmed: 34484816
JAMA Cardiol. 2020 Mar 1;5(3):19-26
pubmed: 31940010
BMC Med. 2021 May 14;19(1):112
pubmed: 33985500
Curr Hypertens Rep. 2020 Sep 3;22(10):78
pubmed: 32880756
Trans R Soc Trop Med Hyg. 2017 Apr 1;111(4):172-177
pubmed: 28673018
Hypertension. 2022 Jul;79(7):1395-1408
pubmed: 35545941
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
PLoS One. 2011;6(7):e22288
pubmed: 21779407
J Hypertens. 2015 Oct;33(10):2039-45
pubmed: 26431192
HIV Med. 2018 Oct;19(9):605-618
pubmed: 30019813
J Int Assoc Provid AIDS Care. 2021 Jan-Dec;20:2325958221996860
pubmed: 33626965
Curr Hypertens Rep. 2012 Jun;14(3):254-60
pubmed: 22427070
Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1113-H1123
pubmed: 30875261
Hypertension. 2016 Dec;68(6):1322-1327
pubmed: 27777357
Circ Res. 2022 Mar 4;130(5):782-799
pubmed: 35239404
Medicine (Baltimore). 2021 Apr 9;100(14):e25236
pubmed: 33832083
BMC Nephrol. 2020 Nov 25;21(1):506
pubmed: 33238919
Am J Physiol Endocrinol Metab. 2019 Dec 1;317(6):E1172-E1181
pubmed: 31689145
PLoS One. 2018 Oct 3;13(10):e0204020
pubmed: 30281618